KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Work In Process: 2018-2020

  • Amneal Pharmaceuticals' Work In Process was N/A to $53.1 million in Q1 2020 from the same period last year, while for Mar 2020 it was $53.1 million, marking a year-over-year change of. This contributed to the annual value of $58.2 million for FY2019, which is 7.45% up from last year.
  • According to the latest figures from Q1 2020, Amneal Pharmaceuticals' Work In Process is $53.1 million, which was down 8.79% from $58.2 million recorded in Q4 2019.
  • In the past 5 years, Amneal Pharmaceuticals' Work In Process registered a high of $58.2 million during Q4 2019, and its lowest value of $50.8 million during Q3 2019.
  • In the last 3 years, Amneal Pharmaceuticals' Work In Process had a median value of $53.6 million in 2018 and averaged $54.0 million.
  • Data for Amneal Pharmaceuticals' Work In Process shows a peak YoY increased of 7.45% (in 2019) over the last 5 years.
  • Amneal Pharmaceuticals' Work In Process (Quarterly) stood at $54.2 million in 2018, then increased by 7.45% to $58.2 million in 2019, then reached $53.1 million in 2020.
  • Its last three reported values are $53.1 million in Q1 2020, $58.2 million for Q4 2019, and $50.8 million during Q3 2019.